Understanding the Roles of Non-coding RNAs and Exosomal Non-Coding RNAs in Diabetic Nephropathy
- PMID: 38591211
- DOI: 10.2174/0115665240287631240321072504
Understanding the Roles of Non-coding RNAs and Exosomal Non-Coding RNAs in Diabetic Nephropathy
Abstract
One of the greatest serious side effects of diabetes is diabetic nephropathy (DN), which is also the key factor in the sometimes-deadly diabetic end-stage renal disease. Progressive renal interstitial fibrosis is closely associated with oxidative stress, and the extracellular matrix is typically a feature of DN. Some RNAs formed by genome transcription that are not translated into proteins are recognized as noncoding RNAs. It has been shown that ncRNAs control apoptosis, inflammatory response, cell proliferation, autophagy, and other pathogenic processes, contributing to the pathogenesis of DN. Exosomes are nano-carriers vesicles that variety in size from 40 to 160 nm. Exosomes are widely present and dispersed in different bodily fluids, plentiful in nucleic acids, lipids, and proteins (microRNA, mRNA, tRNA, lncRNA, circRNA, etc.). Exosomes play a crucial role as messengers for cellular communication. They transport and transmit key signaling molecules, participate in the transfer of information and materials between cells, control cellular physiological processes, and are carefully linked to the beginning and development of many diseases. Herein, we summarized the role of different ncRNAs in DN. Moreover, we highlighted the role of the exosomal form of ncRNAs in the DN pathogenesis.
Keywords: Diabetic nephropathy; circRNA.; exosome; lncRNA; microRNA; non-coding RNAs.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Exosomal ncRNAs: Novel therapeutic target and biomarker for diabetic complications.Pharmacol Res. 2022 Apr;178:106135. doi: 10.1016/j.phrs.2022.106135. Epub 2022 Feb 19. Pharmacol Res. 2022. PMID: 35192956 Review.
-
Noncoding RNAs in Diabetic Nephropathy: Pathogenesis, Biomarkers, and Therapy.J Diabetes Res. 2020 Jun 19;2020:3960857. doi: 10.1155/2020/3960857. eCollection 2020. J Diabetes Res. 2020. PMID: 32656264 Free PMC article. Review.
-
Crosstalk between non-coding RNA and apoptotic signaling in diabetic nephropathy.Biochem Pharmacol. 2024 Dec;230(Pt 3):116621. doi: 10.1016/j.bcp.2024.116621. Epub 2024 Nov 13. Biochem Pharmacol. 2024. PMID: 39542182 Review.
-
Exosomal non-coding RNAs: Emerging roles in bilateral communication between cancer cells and macrophages.Mol Ther. 2022 Mar 2;30(3):1036-1053. doi: 10.1016/j.ymthe.2021.12.002. Epub 2021 Dec 2. Mol Ther. 2022. PMID: 34864204 Free PMC article. Review.
-
Role of exosomal non‑coding RNAs in ovarian cancer (Review).Int J Mol Med. 2024 Oct;54(4):87. doi: 10.3892/ijmm.2024.5411. Epub 2024 Aug 12. Int J Mol Med. 2024. PMID: 39129308 Review.
Cited by
-
Integrated analysis of long non‑coding RNA megacluster, microRNA‑132 and microRNA‑133a and their implications for cardiovascular risk and kidney failure progression in diabetic patients.Exp Ther Med. 2024 Dec 18;29(2):35. doi: 10.3892/etm.2024.12785. eCollection 2025 Feb. Exp Ther Med. 2024. PMID: 39776891 Free PMC article.
-
Discovering diabetes complications-related microRNAs: meta-analyses and pathway modeling approach.BMC Med Genomics. 2025 May 15;18(1):86. doi: 10.1186/s12920-025-02144-1. BMC Med Genomics. 2025. PMID: 40369506 Free PMC article.
References
-
- Schernthaner G.; Mogensen C.E.; Schernthaner G.H.; The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diabetes Vasc Dis Res 2014,11(5),306-323
-
- Lin Y.C.; Chang Y.H.; Yang S.Y.; Wu K.D.; Chu T.S.; Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc 2018,117(8),662-675 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical